For instance, there is growing evidence for enhanced therapeutic efficacy of concurrent PD-1 and CTLA-4 blockade, and the combination of Nivolumab with Ipilimumab was recently granted an accelerated approval by FDA based on results from CheckMate-040 (for patients with hepatocellular carcinoma unsuccessfully treated with sorafenib). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.